

DT12 Rec'd PCT/PTO 24 JAN 2005

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ranjit C. Desai, et al

Int'l Appln.
No. : PCT/US03/23499

Int'l Date
Filed : 25 July 2003 (07/25/2003)

Serial No. : (To be assigned) Case No.: 21173P

Filed : January 24, 2005

For : PPAR ALPHA SELECTIVE COMPOUNDS FOR THE
TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID
DISORDERS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 1-24-05
EXPRESS MAIL NO. EL 989587845 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Ron Schepisi
DATE Jan 24, 2005

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.


In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of references other than the US patents and published patent applications that are cited on the attached form PTO-1449 are enclosed herewith.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: January 24, 2005

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

COMPLETELY KNOWN

Application Number	JP12-6558/PCT/PTO 24 JAN 2005
Filing Date	January 24, 2005
First Named Inventor	Ranjit C. Desai, et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	21173P

1

[illegible][illegible]

DATE OF DEPOSIT	1-24-05
EXPRESS MAIL NO.	EL989587845US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450,	

Date **MAILED BY**
Considered **DATE**

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003